FDA Seeks New Ways To Involve Patients In Regulatory Process
This article was originally published in The Pink Sheet Daily
Executive Summary
Industry hasn’t been shy about suggesting what changes it would like to see in FDA’s existing patient program, and opening of formal docket suggests agency is eager to rethink its approach.
You may also be interested in...
Patient-Focused Drug Development At 10: Where Does It Go From Here?
FDA may conduct more than the 20 required meetings by the end of fiscal year 2017, but how will the patient-focused drug development program find its place in helping generate new drugs?
“Patient Voice” Report Puts Chronic Fatigue Symptoms, Treatments In Benefit/Risk Framework
FDA report on CFS/myalgic encephalomyelitis is first of its kind from the patient-focused drug development initiative under PDUFA V. Incorporating comments from hundreds of patients and caregivers into a structured framework shows how the input may support a benefit/risk assessment for new products.
Woodcock Takes On Rare Disease Challenges In Retirement, Keeps FDA, Industry At Arm’s Length
Recently retired US FDA Principal Deputy Commissioner Janet Woodcock will be advising the Haystack Project, with the goal of helping rare disease organizations encourage creativity in drug development programs without jeopardizing regulatory success, Woodcock told the Pink Sheet in an interview.